These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24184633)

  • 1. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
    Simon M; Stefan N; Borsig L; Plückthun A; Zangemeister-Wittke U
    Mol Cancer Ther; 2014 Feb; 13(2):375-85. PubMed ID: 24184633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.
    Stefan N; Zimmermann M; Simon M; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2014 Dec; 25(12):2144-56. PubMed ID: 25350699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
    Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
    Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
    Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T
    Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
    Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
    Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
    Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
    Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
    Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
    J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A.
    Gholami N; Cohan RA; Razavi A; Bigdeli R; Dashbolaghi A; Asgary V
    J Cell Physiol; 2020 Apr; 235(4):3711-3720. PubMed ID: 31578716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension.
    Simon M; Frey R; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2013 Nov; 24(11):1955-66. PubMed ID: 24168270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
    Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
    Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli.
    Joshi BH; Puri RK
    Protein Expr Purif; 2005 Feb; 39(2):189-98. PubMed ID: 15642470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering of bacterial exotoxins for highly efficient and receptor-specific intracellular delivery of diverse cargos.
    Ryou JH; Sohn YK; Hwang DE; Park WY; Kim N; Heo WD; Kim MY; Kim HS
    Biotechnol Bioeng; 2016 Aug; 113(8):1639-46. PubMed ID: 26773973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
    Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
    Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha.
    Kihara A; Pastan I
    Bioconjug Chem; 1994; 5(6):532-8. PubMed ID: 7873657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a modular immunotoxin connected by polyionic adapter peptides.
    Kleinschmidt M; Rudolph R; Lilie H
    J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells.
    Kunwar S; Pai LH; Pastan I
    J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.